Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Novel Oxabispidine Compounds And Their Use In The Treatment Of Cardiac Arrhythmias

a technology of oxabispidine and compounds, which is applied in the field of new oxabispidine compounds and their use in the treatment of cardiac arrhythmias, can solve problems such as (turning points)

Inactive Publication Date: 2009-10-29
ASTRAZENECA AB
View PDF14 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Benefits of technology

[0280]In the treatment of arrhythmias, compounds of the invention have been found to selectively delay cardiac repolarization and increase refractoriness.
[0294]The compounds of the invention have the advantage that they are effective against cardiac arrhythmias.
[0295]Compounds of the invention may also have the advantage that they may be more efficacious than, be less toxic than, have a broader range of activity (including exhibiting any combination of class I, class II, class III and / or class IV activity (especially class I and / or class Iv activity in addition to class III activity)) than, be more potent than, be longer acting than, produce fewer side effects (including a lower incidence of proarrhythmias such as torsades de pointes) than, be more easily absorbed than, or that they may have other useful pharmacological properties over, compounds known in the prior art.Biological TestsTest APrimary Electrophysiological Effects in Anaesthetised Guinea Pigs

Problems solved by technology

One of the key disadvantages of hitherto known drugs which act by delaying repolarization (class III or otherwise) is that they all are known to exhibit a unique form of proarrhythmia known as torsades de pointes (turning of points), which may, on occasion be fatal.

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Novel Oxabispidine Compounds And Their Use In The Treatment Of Cardiac Arrhythmias
  • Novel Oxabispidine Compounds And Their Use In The Treatment Of Cardiac Arrhythmias
  • Novel Oxabispidine Compounds And Their Use In The Treatment Of Cardiac Arrhythmias

Examples

Experimental program
Comparison scheme
Effect test

preparation d

1-[3-(9-Oxa-3,7-diazabicyclo[3.3.1]non-3-yl)propanoyl]indoline-5-carbonitrile, hydrochloride salt

(i) 5-Bromo-2,3-dihydro-1H-indole

[0323]NaBH3CN (19.3 g, 0.3061 mol) was added in 3 portions to a cooled (15° C.) solution of 5-bromoindole (20 g, 0.10 mol) in glacial acetic acid (500 mL) and stirred for 2 h at this same temperature. The reaction mixture was quenched with water, cooled and basified with a sodium hydroxide pellet. It was then extracted with diethyl ether. The organic layer was washed with water and brine, dried over sodium sulfate, concentrated and purified by column chromatography over silica gel to give the sub-title compound as a pale yellow solid. Yield: 20 g.

(ii) 5-Bromo-1-(trifluoroacetyl)indoline

[0324]5-Bromo-2,3-dihydro-1H-indole (20 g, 0.1010 mol; see step (i) above) was taken in (100 mL) of DCM and cooled to 0° C. Trifluoroacetic anhydride (42.42 g, 0.2020 mol) was added dropwise to the reaction mixture, which was then stirred for 30 min. The reaction mixture wa...

preparation b

4-Cyano-N-[2-(9-oxa-3,7-diazabicyclo[3.3.1]non-3-yl)ethyl]benzene-sulfonamide

(i) N-(2-Bromoethyl)-4-cyanobenzenesulfonamide

[0330]To an ice cooled solution of 2-bromoethylamine hydrogenbromide (12.2 g, 0.0595 mol) in dry dichloromethane (100 mL) was added triethylamine and the mixture stirred for 15 min. 4-Cyanobenzenesulfonyl chloride (10 g, 0.0486 mol) in dichloromethane was added, dropwise. Stirring was continued at RT for 1 h. The reaction mixture was diluted with dichloromethane, washed with water, followed by brine, then dried over sodium sulfate. Solvents were evaporated and the residue crystallized from petroleum ether to give 12.5 g of the sub-title compound as a pale yellow solid.

(ii) 7-[2-(4-Cyanobenzenesulfonylamino)ethyl]-9-oxa-3,7-diazabicyclo-[3.3.1]nonane-3-carboxylic acid tert-butyl ester

[0331]A suspension of N-(2-bromoethyl)-4-cyanobenzenesulfonamide (5 g, 0.017 mol; see step (i) above), 9-oxa-3,7-diaza-bicyclo[3.3.1]nonane-3-carboxylic acid tert-butyl ester (3.96 g...

example 1

N-(2-{7-[(2S)-3-(4-Cyanophenoxy)-2-hydroxypropyl]-9-oxa-3,7-diaza-bicyclo[3.3.1]non-3-yl}ethyl)-1-phenylmethanesulfonamide

[0426]4-{(2S)-3-[7-(2-Aminoethyl)-9-oxa-3,7-diazabicyclo[3.3.1]non-3-yl]-2-hydroxypropoxy}benzonitrile (0.096 g, 0.28 mmol; see step Preparation A above) was dissolved in a 1:2 ratio of DCM:acetonitrile (3 mL). Triethylamine (0.17 g, 1.68 mmol) was added, followed by phenylmethanesulfonyl chloride (0.068 g, 0.36 mmol). The mixture was stirred at room temperature overnight with K2CO3 (0.38 g, 2.77 mmol) to ensure that the free base of triethylamine was in the reaction mixture. The reaction mixture was filtered and the filtrate concentrated under reduced pressure. Purification by preparative HPLC gave 0.1 g (72%) of the title compound.

[0427]1H NMR (400 MHz, CD3OD) δ 7.64-7.66 (2H, d), 7.36-7.43 (5H, m), 7.05-7.07 (2H, m), 4.41 (3H, m), 4.17 (2H, m), 4.08 (2H, m), 3.62-3.7 (2H, m), 3.12-3.4 (8H, m), 2.72-2.86 (2H, m), 2.46-2.59 (2H, m).

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

PropertyMeasurementUnit
conduction velocityaaaaaaaaaa
action potential durationaaaaaaaaaa
chemical curiositiesaaaaaaaaaa
Login to View More

Abstract

There is provided compounds of formula (I), wherein R1, R2, R3, R4, R41 to R46, A, B and G have meanings given in the description, which are useful in the prophylaxis and in the treatment of arrhythmias, in particular atrial and ventricular arrhythmias.

Description

FIELD OF THE INVENTION[0001]This invention relates to novel pharmaceutically useful compounds, in particular compounds which are useful in the treatment of cardiac arrhythmias.BACKGROUND AND PRIOR ART[0002]Cardiac arrhythmias may be defined as abnormalities in the rate, regularity, or site of origin of the cardiac impulse or as disturbances in conduction which causes an abnormal sequence of activation. Arrhythmias may be classified clinically by means of the presumed site of origin (i.e. as supraventricular, including atrial and atrioventricular, arrhythmias and ventricular arrhythmias) and / or by means of rate (i.e. bradyarrhythmias (slow) and tachyarrhymias (fast)).[0003]In the treatment of cardiac arrhythmias, the negative outcome in clinical trials (see, for example, the outcome of the Cardiac Arrhythmia Suppression Trial (CAST) reported in New England Journal of Medicine, 321, 406 (1989)) with “traditional” antiarrhythmic drugs, which act primarily by slowing the conduction velo...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(United States)
IPC IPC(8): A61K31/537C07D498/08A61P9/06C07D
CPCC07D498/08A61P9/00A61P9/06A61K31/438
Inventor BJORE, ANNIKABONN, PETERGRAN, ULRIKKAJANUS, JOHANOLSSON, CHRISTINAPONTEN, FRITIOF
Owner ASTRAZENECA AB
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com